Consensus Report
ApoB
Strong Consensus
out of 5
Based on 13 videos (18 hours analyzed) across the experts · Updated 2026-06-10
Expert Positions
The Verdict
The experts who cover it agree: ApoB — the count of atherogenic particles — is a more accurate predictor of cardiovascular risk than standard LDL-C, and it's worth measuring (with a doctor) rather than relying on a basic cholesterol panel. Four of the five experts endorse this; Bryan Johnson has no direct coverage in the analyzed videos.
Where They Disagree
How aggressively and how early to lower ApoB is the main split: Attia advocates pushing ApoB to childhood-low levels starting young, while the other experts endorse measuring/lowering ApoB without committing to those specific aggressive targets in the analyzed videos.
Diet vs. medication emphasis differs: Attia is explicit that lifestyle change alone is often insufficient to hit optimal ApoB targets and leans on pharmacology, whereas Hyman frames insulin resistance, diet, and lifestyle as the root drivers to address first.
+ 1 more disagreement in the full report
About This Analysis
This consensus report on ApoB is based on 13 videos (18 hours analyzed) from five longevity experts: Andrew Huberman, Peter Attia, Rhonda Patrick, Bryan Johnson, and Mark Hyman. Each expert's position was independently analyzed from their published video content, including lectures, podcast episodes, and Q&A sessions with 1,000+ guest scientists.
The full report includes 9 key findings, expert deep dives with direct video citations and timestamps, risk considerations, and related supplement synergies.
Frequently Asked Questions
What do experts agree on about apob?
The experts who cover it agree: ApoB — the count of atherogenic particles — is a more accurate predictor of cardiovascular risk than standard LDL-C, and it's worth measuring (with a doctor) rather than relying on a basic cholesterol panel. Four of the five experts endorse this; Bryan Johnson has no direct coverage in the analyzed videos.
Where do the experts disagree on apob?
How aggressively and how early to lower ApoB is the main split: Attia advocates pushing ApoB to childhood-low levels starting young, while the other experts endorse measuring/lowering ApoB without committing to those specific aggressive targets in the analyzed videos. Diet vs. medication emphasis differs: Attia is explicit that lifestyle change alone is often insufficient to hit optimal ApoB targets and leans on pharmacology, whereas Hyman frames insulin resistance, diet, and lifestyle as the root drivers to address first. Attia engages heavily with statins, ezetimibe, bempedoic acid, and PCSK9 inhibitors as tools to lower ApoB; the other experts in this report focus more on the measurement-and-testing argument than on a specific drug protocol.
How strong is the expert consensus on apob?
The consensus on apob scores 3.9/5 — a strong level of agreement across Huberman, Attia, Patrick, Johnson, and Hyman, based on their public videos.
Common Questions
Related Reports
Unlock the Full Report
Get dosages, timing protocols, expert deep dives with video citations, and risks for ApoB.
Every recommendation traces back to a specific expert, video, and timestamp.
$9/month or $79/year · Cancel anytime